Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 701–800 of 1,016
Genomics and Transcriptomics: The Powerful Technologies in Precision Medicine
Khodadadian, A., Darzi, S., Haghi‐Daredeh, S., Eshaghi, F. S., Babakhanzadeh, E., Mirabutalebi, S. H., & Nazari, M. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s249970 · Cited by 94
Li, X., Zhao, Y., Zhang, T., & Xing, D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001240 · Cited by 84
Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency
Wang, M., Hou, D., Lv, G., Li, R.-X., Hu, X., Wang, Z., Zhang, N., Yi, L., Xu, W., & Wang, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121139 · Cited by 81
Spatial structure impacts adaptive therapy by shaping intra-tumoral competition
Strobl, M. A. R., Gallaher, J. A., West, J., Robertson‐Tessi, M., Maini, P. K., & Anderson, A. R. A. (2022) · Communications Medicine · doi:10.1038/s43856-022-00110-x · Cited by 98
“In the clinic, the main strategy for managing cancer drug resistance is to switch treatment with the aim of finding an agent to which the tumour is still susceptible [3,4].”
BackgroundImmunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 99
Ding, X. Q., Ting, N. L.-N., Wong, C. C., Huang, P., Бакурадзе, Н., Jiang, L., Liu, C., Lin, Y., Li, S., Liu, Y., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.004 · Cited by 91
Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo
Jia, D., Tan, Y., Liu, H., Ooi, S., Li, L., Wright, K. E., Bennett, S. A. L., Addison, C., & Wang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5819 · Cited by 86
“Among chemotherapeutic drugs used widely for patients with breast cancers, 5-fluorouracil (targeting thymidylate synthase and DNA synthesis), doxorubicin (targeting topoisomerase II), and paclitaxel (targeting cytoskeleton structure tubulin) are three well-defined first-line agents [17, 18].”
Karpel‐Massler, G., Horst, B. A. J., Shu, C., Chau, L., Tsujiuchi, T., Bruce, J. N., Canoll, P., Greene, L. A., Angelastro, J. M., & Siegelin, M. D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2827 · Cited by 86
“Discussion Cancer cells typically develop primary or secondary resistance to apoptosis (36).”
Wong, V. K. W., Zeng, W., Chen, J., Yao, X. J., Leung, E. L. H., Wang, Q. Q., Chiu, P., Ko, B. C. B., & Law, B. Y. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00351 · Cited by 80
“Cancer cells are frequently resistant to apoptosis (Holohan et al., 2013).”
BackgroundRodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Li, M., Teh, C., Ang, C. Y., Tan, S. Y., Luo, Z. Y., Qu, Q., Zhang, Y., Korzh, V. P., & Zhao, Y. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502469 · Cited by 80
Wang, Z., He, Q., Zhao, W., Luo, J., & Gao, W. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.017 · Cited by 81
Wang, C., Guan, W., Peng, J., Chen, Y., Xu, G., & Dou, H. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.015 · Cited by 82
Jamroškovič, J., Doimo, M., Chand, K., Obi, I. R., Kumar, R., Brännström, K., Hedenström, M., Das, R. N., Akhunzianov, A., Deiana, M., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11232 · Cited by 82
“2 Thus, inhibition of STAT3 phosphorylation blocks its activation and represents one of the main strategies in STAT3-related drug development.”
Mitochondrial targeted strategies and their application for cancer and other diseases treatment
Li, Q., & Huang, Y. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00481-0 · Cited by 86
“The mechanisms underlying MDR are complicated, generally divide into the acquired resistance including enhanced drug efflux, decreased cellular uptake, changes of drug targets and intrinsic resistance including blockade apoptosis and enhanced DNA repair (Patel et al. 2013; Holohan et al. 2013).”
BackgroundFaheem, M. M., Seligson, N. D., Ahmad, S. M., Rasool, R. U., Gandhi, S. G., Bhagat, M., & Goswami, A. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0286-z · Cited by 92
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II
Xiong, K., Qian, C., Yuan, Y., Wei, L., Liao, X., He, L., Rees, T. W., Chen, Y., Wan, J., Ji, L., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202006089 · Cited by 84
Intracellular Ca2 + Imbalance Critically Contributes to Paraptosis
Kim, E., Lee, D. M., Seo, M. J., Lee, H. J., & Choi, K. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607844 · Cited by 95
Therapeutic potential of Scutellaria baicalensis Georgi in lung cancer therapy
Li, X., Gao, Y., Chen, S., Sun, J., Wu, J., & Meng, X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153727 · Cited by 83
Current challenges in metastasis research and future innovation for clinical translation
Parker, A. L., Benguigui, M., Fornetti, J., Goddard, E. T., Lucotti, S., Insua‐Rodríguez, J., & Wiegmans, A. P. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10144-5 · Cited by 89
“Resistance mechanisms to conventional chemotherapies can be due to chemotherapyinduced acquisition of de novo genomic alterations [96], phenotypic adaptation to cytotoxic stress [97] or result from the expansion of pre-existing clones [98].”
BackgroundLv, L. L., Liu, H.-G., Dong, S., Yang, F., Wang, Q., Guo, G., Pan, Y., & Zhang, X. (2016) · Tumor Biology · doi:10.1007/s13277-015-4755-6 · Cited by 90
Zhao, D., Zhang, H., Yang, S., He, W., & Luan, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.10.029 · Cited by 83
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells
Yong, S., Chung, J. Y., Song, Y., Kim, J., Ra, S., & Kim, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119401 · Cited by 84
Tomar, V. S., Patil, V. S., & Somasundaram, K. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09502-7 · Cited by 79
The Impact of Diet and Exercise on Drug Responses
Niederberger, E., & Parnham, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147692 · Cited by 88
“Mutations may be induced by the drugs themselves, as in chemotherapy or, in other cases, by causing the organism to modify the drug [3].”
BackgroundTumour Microenvironment Stress Promotes the Development of Drug Resistance
Seebacher, N. A., Krchniaková, M., Stacy, A. E., Skoda, J., & Jansson, P. J. (2021) · Antioxidants · doi:10.3390/antiox10111801 · Cited by 89
“This resistance to chemotherapeutic agents may be independent of their structure and pharmacological mechanism, known as MDR [57].”
BackgroundOrganoid screening reveals epigenetic vulnerabilities in human colorectal cancer
Toshimitsu, K., Takano, A., Fujii, M., Togasaki, K., Matano, M., Takahashi, S., Kanai∥, T., & Sato, T. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00984-x · Cited by 91
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance
Zhu, Y., Xia, T., Chen, D.-Q., Xiong, X., Shi, L., Zuo, Y., Xiao, H., & Liu, L. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101016 · Cited by 88
Liang, S.-Q., Marti, T. M., Dorn, P., Froment, L., Hall, S., Berezowska, S., Kocher, G. J., Schmid, R. A., & Peng, R. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.195 · Cited by 82
Ai, Y., Zhu, B., Ren, C., Kang, F., Li, J., Huang, Z., Lai, Y., Peng, S., Ding, K., Tian, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01203 · Cited by 80
Siddiqui, S., Ahmad, M. S., Jafri, A., Afzal, M. F., & Arshad, M. (2017) · Nutrition and Cancer · doi:10.1080/01635581.2017.1310260 · Cited by 81
“Several studies have reported that natural products could improve the sensitivity of resistant cancers to existing chemotherapy drugs (4,5).”
BackgroundFolding graft copolymer with pendant drug segments for co-delivery of anticancer drugs
Tai, W., Mo, R., Lü, Y., Jiang, T., & Gu, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.004 · Cited by 81
“Evolution of drug resistance in cancer cells has been attributed as a major factor in the failure of many forms of monotherapy [1,2].”
Pénzváltó, Z., Lánczky, A., Lénárt, J., Meggyesházi, N., Krenács, T., Szoboszlai, N., Denkert, C., Pete, I., & Győrffy, B. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-837 · Cited by 88
“Targeting EGFR has a moderate effect in ovarian cancer [21], probably due to collateral escaping mechanisms [22,23], which could be avoidable by targeting downstream members of the oncogenic pathway.”
BackgroundGurung, A. B., Bhattacharjee, A., & Ali, M. A. (2016) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2016.09.004 · Cited by 85
“[2] Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG.”
BackgroundLin, M., Gao, Y., Diefenbach, T. J., Shen, J. K., Hornicek, F. J., Park, Y. I., Xu, F., Lu, T. J., Amiji, M. M., & Duan, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15321 · Cited by 78
New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy
Datta, A., & Brosh, R. M. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00059 · Cited by 84
Onafuye, H., Pieper, S., Mulac, D., Cinatl, J. J., Wass, M. N., Langer, K., & Michaelis, M. (2019) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.10.166 · Cited by 84
Lin, Q., Wang, X., & Hu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216318 · Cited by 78
Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons
Hollebecque, A., Malka, D., Ferté, C., Ducreux, M. P., & Boige, V. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.12.005 · Cited by 84
“The third challenge is that the efficacy of targeted therapies is limited by drug resistance [129–131].”
BackgroundWang, H., Zhao, X., Guo, C., Ren, D., Zhao, Y., Xiao, W. L., & Jiao, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139136 · Cited by 79
“The over-expression of BCL-2 result in cancer cells resistance to chemotherapy drug-induced apoptosis [33].”
BackgroundNanoparticle-Mediated Mitochondrial Damage Induces Apoptosis in Cancer
Mallick, A., More, P. A., Syed, M. M. K., & Basu, S. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b00263 · Cited by 81
Ma, J., Song, X., Xu, X., & Mou, Y. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.031 · Cited by 78
Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
Shen, D., Chen, W., Zhu, J., Wu, G., Shen, R., Xi, M., & Sun, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112117 · Cited by 73
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
Ma, L., Ma, R., Wang, Z., Yiu, S., & Zhu, G. (2016) · Chemical Communications · doi:10.1039/c6cc04354b · Cited by 82
Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics
Patel, H., Nilendu, P., Jahagirdar, D., Pal, J. K., & Sharma, N. K. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394538 · Cited by 85
“There are various ways in which TME plays a role in drug resistance such as by not allowing the drug to enter inside the tumor tissue by formation of a tough ECM network, modulation of cell-cell communication and changes in the level of soluble components including matricellular proteins, cytokines, metabolites, RNA,…”
BackgroundInfluentialTIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer
Izumi, D., Toden, S., Ureta, E., Ishimoto, T., Baba, H., & Goel, A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1493-5 · Cited by 78
Lei, H.-M., Zhang, K., Wang, C. H., Wang, Y., Zhuang, G., Lu, L., Zhang, J., Shen, Y. H., Chen, H., & Zhu, L. (2019) · Theranostics · doi:10.7150/thno.35729 · Cited by 82
“Drug-resistant cells often bear activated and upregulated ALDH1A1, representing an important mechanism whereby tumors can resist drug treatment [3, 9, 34, 35].”
Circulating platelets as liquid biopsy sources for cancer detection
Antunes‐Ferreira, M., Koppers‐Lalic, D., & Würdinger, T. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12859 · Cited by 80
Ge, C., Zhang, S., Mu, H., Shaojun, Z., Tan, Z., Huang, X., Chen, X., Zou, J., Zhu, Y., Dong, F., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774957 · Cited by 87
“A large amount of evidence has confirmed that ferroptosis induction plays a predominant role against certain chemoresistant cancer cells that are in a high mesenchymal state or escaping drug treatment (Holohan et al., 2013).”
BackgroundNel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 84
Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets
Alatise, K. L., Gardner, S., & Alexander-Bryant, A. A. (2022) · Cancers · doi:10.3390/cancers14246246 · Cited by 100
“The heterogeneity of ovarian tumors makes treatment more difficult because there exists a small subgroup of cancer stem cells (CSCs) or tumor-initiating cells that have been shown to induce chemoresistance and cancer relapse [8].”
BackgroundSprouse, A. A. (2014) · PubMed · doi:10.7912/c2/305 · Cited by 89
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Erazo, T., Lorente, M., López-Plana, A., Muñoz-Guardiola, P., Fernández-Nogueira, P., García-Martínez, J. A., Bragado, P., Fuster, G., Salazar, M., Espadaler, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1808 · Cited by 76
“The majority of current anticancer treatments activate apoptosis, and resistance to chemotherapy is a major challenge in cancer (24).”
BackgroundCancer’s Achilles’ Heel: Apoptosis and Necroptosis to the Rescue
Dasgupta, A., Nomura, M., Shuck, R. L., & Yustein, J. T. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010023 · Cited by 87
Fageria, L., Pareek, V., Dilip, R. V., Bhargava, A., Pasha, S. S., Laskar, I. R., Saini, H., Dash, S., Chowdhury, R., & Panwar, J. (2017) · ACS Omega · doi:10.1021/acsomega.7b00045 · Cited by 80
Regulatory players of DNA damage repair mechanisms: Role in Cancer Chemoresistance
Sakthivel, K. M., & Hariharan, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.035 · Cited by 83
miR-149 in Human Cancer: A Systemic Review
He, Y., Yu, D., Zhu, L., Zhong, S., Zhao, J., & Tang, J. (2017) · Journal of Cancer · doi:10.7150/jca.21044 · Cited by 79
“Cancer resistance to chemotherapy, molecularly targeted therapies, and other anti-cancer drugs limits treatment effectiveness.[37] Studies have shown that miR-149 participates in regulating drug sensitivity and cancer resistance.”
BackgroundGreene, J. M., Gevertz, J. L., & Sontag, E. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.18.00087 · Cited by 91
“dS dt r 1 − S + R K S − e + αu t S − du t S + γR, (1)”
BackgroundInfluentialDrug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting
Lu, B., Huang, X., Mo, J., & Zhao, W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00084 · Cited by 76
“…chemotherapies owing to various enhanced features, including ATP-binding cassette (ABC) transporter proteins, aldehyde dehydrogenase (ALDH) activity, anti-apoptotic proteins, DNA damage repair and activation of key pro-survival signaling molecules such as Notch and NF-κB (Holohan et al., 2013).”
BackgroundInfluentialWang, B., Ma, L., Wang, J., Lei, Z., Gupta, P., Zhao, Y., Li, Z., Liu, Y., Zhang, X., Li, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00335 · Cited by 76
Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer
Zhang, Y., Li, M., & Hu, C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.061 · Cited by 76
The Use of Conformational Restriction in Medicinal Chemistry
Pinheiro, P. D. S. M., Rodrigues, D. A., Maia, R. D. C., Thota, S., & Fraga, C. A. M. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712205025 · Cited by 85
Monofunctional Platinum(II) Anticancer Agents
Jin, S., Guo, Y., Guo, Z., & Wang, X. (2021) · Pharmaceuticals · doi:10.3390/ph14020133 · Cited by 79
Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance
Genovese, I., Carinci, M., Modesti, L., Aguiari, G., Pinton, P., & Giorgi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094770 · Cited by 82
“To date, two types of chemoresistance development mechanisms have been reported: intrinsic and acquired [1,2].”
BackgroundDeng, X., Kong, F., Li, S., Jiang, H., Dong, L., Xu, X., Zhang, X., Yuan, H., Xu, Y., Chu, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03753-1 · Cited by 77
Microenvironment-triggered multimodal precision diagnostics
Hao, L., Rohani, N., Zhao, R. T., Pulver, E. M., Mak, H. H., Kelada, O. J., Ko, H., Fleming, H. E., Gertler, F. B., & Bhatia, S. N. (2021) · Nature Materials · doi:10.1038/s41563-021-01042-y · Cited by 79
“Greater than 80% of the detected MMP9 protein expression overlapped with FAM-staining, which marks PRISM in the tumour (Fig.”
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
“However, challenges and limitations remain, including the development of resistance to targeted therapies over time [224], potential side effects ranging from mild skin rashes or diarrhea to severe liver toxicity or heart problems [225], limited responsiveness in certain cancer types or patients…”
BackgroundRoles of tumor heterogeneity in the development of drug resistance: A call for precision therapy
Wu, D., Wang, D. C., Cheng, Y., Qian, M., Zhang, M., Shen, Q., & Wang, X. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.006 · Cited by 82
Tanwar, D. K., Parker, D. J., Gupta, P., Spurlock, B., Alvarez, R. D., Basu, M. K., & Mitra, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11047 · Cited by 83
“Relapse with chemoresistant disease may be triggered or maintained by cancer stem cells (CSCs) [40].”
BackgroundInfluentialPEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells
Kim, S., Lee, Y. K., Lee, J. Y., Hong, J. H., & Khang, D. (2017) · Nanotechnology · doi:10.1088/1361-6528/aa8c31 · Cited by 78
Purushothaman, B., Choi, J. H., Park, S.-J., Lee, J., Samson, A. A. S., Hong, S., & Song, J. M. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01923a · Cited by 76
Gavini, J., Dommann, N., Jakob, M. O., Keogh, A., Bouchez, L. C., Karkampouna, S., Julio, M. K., Medová, M., Zimmer, Y., Schläfli, A. M., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1989-z · Cited by 80
Ren, H., Bakas, N. A., Vamos, M., Chaikuad, A., Limpert, A. S., Wimer, C. D., Brun, S. N., Lambert, L. J., Tautz, L., Celeridad, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00873 · Cited by 82
Dowling, C. M., Hollinshead, K. E. R., Grande, A. D., Pritchard, J. R., Zhang, H., Dillon, E., Haley, K. E., Papadopoulos, E., Mehta, A. K., Bleach, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc4897 · Cited by 81
Li, Y., Duan, Y., Li, Y., Gu, Y., Zhou, L., Xiao, Z., Yu, X., Cai, Y., Cheng, E., Liu, Q., et al. (2024) · Exploration · doi:10.1002/exp.20230117 · Cited by 94
The Cancer Antioxidant Regulation System in Therapeutic Resistance
Gu, X., Mu, C., Zheng, R., Zhang, Z., Zhang, Q., & Liang, T. (2024) · Antioxidants · doi:10.3390/antiox13070778 · Cited by 92
“More details can be found in several excellent reviews [21,38].”
BackgroundDysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 80
He, Y., Xing, L., Cui, P., Zhang, J.-L., Zhu, Y., Qiao, J.-B., Lyu, J.-Y., Zhang, M., Luo, C.-Q., Zhou, Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.001 · Cited by 75
Seo, H., Ku, J. M., Choi, H. S., Woo, J. K., Lee, B. H., Kim, D. S., Song, H. J., Jang, B.-H., Shin, Y. C., & Ko, S.-G. (2017) · Oncology Reports · doi:10.3892/or.2017.5752 · Cited by 78
“Based on tumor response to the initial therapy, cancer resistance can be seperated into two categories, intrinsic or acquired (1,3).”
BackgroundInfluentialBrachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer
Shah, S. R., David, J. M., Tippens, N. D., Mohyeldin, A., Martínez-Gutiérrez, J. C., Ganaha, S., Schiapparelli, P. V., Hamilton, D. H., Palena, C., Levchenko, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.057 · Cited by 80
“In addition, numerous studies have shown that these TICs are particularly chemo- and radio-resistant, providing a source for tumor recurrence after therapy (Frank et al., 2010; Holohan et al., 2013; Hsu et al., 2012).”
BackgroundPoli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 75
“Resistance to standard antiproliferative chemotherapy and radiation was initially considered an intrinsic feature of normal SCs and CSCs, acquired through multiple independent mechanisms, such as high expression of drug efflux pumps and relative resistance to oxidative stress or DNA damage [141].”
BackgroundLim, W. Q., Yang, G., Phua, S. Z. F., Chen, H., & Zhao, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b04557 · Cited by 77
Antitumor Drugs and Their Targets
Dembić, Z. (2020) · Molecules · doi:10.3390/molecules25235776 · Cited by 81
Cascade Drug-Release Strategy for Enhanced Anticancer Therapy
Zhang, X., Wang, S., Cheng, G., Yu, P., Chang, J. K., & Chen, X. S. (2021) · Matter · doi:10.1016/j.matt.2020.10.002 · Cited by 76
Pleiotropic Roles of ABC Transporters in Breast Cancer
He, J., Fortunati, E., Liu, D., & Li, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063199 · Cited by 83
“P-glycoprotein, P-gp, and ABCB1), which is distributed in nearly all normal tissues at various levels but is found ov rexpressed in m y tumours [9].”
BackgroundInfluentialSchoetz, U., Klein, D., Hess, J., Shnayien, S., Spoerl, S., Orth, M., Mutlu, S., Hennel, R., Sieber, A., Ganswindt, U., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04454-5 · Cited by 74
“Defects in the regulation of cell death modalities, hyperactivated survival signaling, amplified detoxification of xenobiotics and/or reactive oxygen species, and accelerated DNA repair are commonly observed [1].”
BackgroundBukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 80
“Extrinsic resistance would compensate for the therapeutic effects of previously used drugs, and this could occur as a result of a variety of adaptive responses, including the modulation of signaling pathways, activation of alternative signaling pathways, and increased expression of the therapeutic target [41].”
BackgroundFerroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 84
““Tolerance” is the ability of cells to survive ephemeral exposure to therapeutic concentrations of drugs, and “persistence” is the ability of a sub-population of cell clones to survive in a treatment (Holohan et al., 2013; Holden, 2015).”
BackgroundABC transporters in CSCs membranes as a novel target for treating tumor relapse
Zinzi, L., Contino, M., Cantore, M., Capparelli, E., Leopoldo, M., & Colabufo, N. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00163 · Cited by 81
Chen, Y., Tezcan, O., Li, D., Beztsinna, N., Lou, B., Etrych, T., Ulbrich, K., Metselaar, J. M., Lammers, T., & Hennink, W. E. (2017) · Nanoscale · doi:10.1039/c7nr03592f · Cited by 78
Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0339-0 · Cited by 80
Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer
Vos, P. D., Leedman, P. J., Filipovska, A., & Rackham, O. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03163-9 · Cited by 84
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour, G., Jadidi‐Niaragh, F., Jahromi, A. S., Zandi, K., & Hojjat‐Farsangi, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5059-1 · Cited by 79
Lin, Y., Zhao, W.-R., Shi, W., Zhang, J., Zhang, K.-Y., Ding, Q., Chen, X., Tang, J., & Zhou, Z.-Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00764 · Cited by 76
“org 9 ATP-binding cassette (ABC) transporter family including multi-drug resistance protein 1 (MDR1; also known as Pglycoprotein and ABCB1), MDR-associated protein 1 (MRP1; also known as ABCC1) and breast cancer resistance protein (BCRP; also known as ABCG2) regulates the process of drug efflux, which also overexpress…”
BackgroundChallenges and Therapeutic Opportunities of Autophagy in Cancer Therapy
Silva, V. R., Neves, S. P., Santos, L. D. S., Dias, R. B., & Bezerra, D. P. (2020) · Cancers · doi:10.3390/cancers12113461 · Cited by 81
“In addition, tumors use various chemotherapy resistance strategies, such as activating alternative pathways, increasing drug efflux and mutations in the drug target [5].”
BackgroundApoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy
Arguello, O. A. D., & Haisma, H. J. (2021) · Cancers · doi:10.3390/cancers13071543 · Cited by 84
“The most common treatment courses include chemotherapy, surgery, and radiation [2], which, in many cases, are not effective and can cause multisystemic toxicity.”
BackgroundShao, N., Yuan, L., Ma, P., Zhou, M., Xiao, X., Cong, Z., Wu, Y., Xiao, G., Fei, J., & Liu, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00452 · Cited by 75
DRESIS: the first comprehensive landscape of drug resistance information
Sun, X., Zhang, Y., Li, H., Zhou, Y., Shi, S., Chen, Z., He, X., Zhang, H., Li, F., Yin, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac812 · Cited by 82
“tance or to optimize the available regimens for disease treatment (33,35,52,86).”
BackgroundA Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer
Savage, P., Blanchet-Cohen, A., Revil, T., Badescu, D., Saleh, S. M. I., Wang, Y.-C., Zuo, D., Liu, L., Bertos, N. R., Munoz-Ramos, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.015 · Cited by 72
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.